{"columns":["population_id","label","definition","strata","primary_outcome_ids","network_status","notes"],"rows":[["P01","Type 2 diabetes (adults)","Adults (18 years or older) with type 2 diabetes.","S0 no glucose lowering drug (lifestyle only); S1 one or more non insulin glucose lowering drugs; S2 basal insulin with or without non insulin drugs; S3 prandial, premixed or basal bolus insulin with or without other drugs; S4 mixed background (no stratum reaches 80 percent of participants)","O01;O02;O20;O21;O22","primary","Glycemic and weight networks are built within S0 to S3; S4 trials enter only the pooled type 2 diabetes network used for patient important outcomes and a pooled sensitivity analysis. Weight management trials in type 2 diabetes (for example STEP 2 and SURMOUNT-2) also report O10 and O11 in their stratum."],["P02","Overweight or obesity without diabetes (adults)","Adults with BMI 27 kg/m2 or higher with at least one weight related condition or BMI 30 kg/m2 or higher (or the Asian thresholds used by the trial) and without diabetes. Includes trials enrolling people with established cardiovascular disease and overweight or obesity.",null,"O10;O20;O21","primary",null],["P02W","Weight maintenance after a GLP-1 receptor agonist containing run in","Participants randomized after a run in on a GLP-1 receptor agonist containing drug to continuation; withdrawal or another maintenance strategy. Tolerability and response enrichment criteria of the run in are recorded separately.",null,"O12","secondary","Not transitive with initiation trials; never pooled with P02. The run in drug and dose are effect modifiers."],["P03","Children and adolescents with obesity","Participants aged 6 to 17 years with obesity by age and sex specific BMI criteria.",null,"O13A;O10","primary",null],["P04","Children and adolescents with type 2 diabetes","Participants aged 10 to 17 years with type 2 diabetes.",null,"O01;O04","primary",null],["P05","Type 1 diabetes","People with type 1 diabetes receiving insulin; GLP-1 receptor agonist containing drugs as adjunct.",null,"O01;O30;O31","primary",null],["P06","Prediabetes or impaired glucose regulation","Adults with prediabetes enrolled on a glycemic criterion without an obesity criterion.",null,"O14","secondary","Trials enrolling on both obesity and prediabetes belong to P02 and report O14 there."],["P07A","Heart failure with left ventricular ejection fraction above 40 percent","Adults with heart failure and LVEF above 40 percent (mildly reduced or preserved).",null,"O40;O41","primary","Restriction to LVEF 50 percent or more is a sensitivity analysis. Never pooled with P07B."],["P07B","Heart failure with LVEF 40 percent or lower","Adults with heart failure with reduced ejection fraction.",null,"O40;O41","primary","Never pooled with P07A."],["P08A","Chronic kidney disease with diabetes","Adults with chronic kidney disease and type 2 diabetes enrolled on a kidney criterion.",null,"O50;O51","primary","The same trials also contribute to P01 patient important outcome networks."],["P08B","Chronic kidney disease without diabetes","Adults with chronic kidney disease without diabetes.",null,"O50;O51","primary","Pooling P08A and P08B is a sensitivity analysis only."],["P09","Metabolic dysfunction associated steatotic liver disease or steatohepatitis","Adults with MASLD or biopsy confirmed MASH (formerly NAFLD and NASH).",null,"O60;O61","primary","Resolution of steatohepatitis and fibrosis improvement analyzed separately."],["P10","Obstructive sleep apnea","Adults with moderate to severe obstructive sleep apnea.",null,"O70","primary","Positive airway pressure use at baseline is an effect modifier."],["P11","Knee osteoarthritis","Adults with knee osteoarthritis (with or without obesity).",null,"O80","primary",null],["P12","Polycystic ovary syndrome","Women with polycystic ovary syndrome.",null,"O90A;O10B","primary",null],["P13A","Alzheimer disease","People with mild cognitive impairment or dementia due to Alzheimer disease.",null,"O100A","primary",null],["P13B","Parkinson disease","People with Parkinson disease.",null,"O101","primary",null],["P14A","Alcohol use disorder","People with alcohol use disorder or hazardous drinking.",null,"O110A;O110B","primary",null],["P14B","Tobacco use","People who smoke or use other tobacco products.",null,"O111","primary",null],["P14C","Opioid use disorder","People with opioid use disorder.",null,"O112","primary",null],["P14D","Stimulant use disorder","People with cocaine or amphetamine type stimulant use disorder.",null,"O113","primary",null],["P14E","Cannabis use disorder","People with cannabis use disorder.",null,"O114","primary",null],["P15","Antipsychotic associated weight gain and severe mental illness","People with schizophrenia or other severe mental illness with weight gain on antipsychotics.",null,"O10B","primary","Antipsychotic drug is an effect modifier."],["P99","Other conditions","Any other condition studied in a randomized trial of a GLP-1 receptor agonist containing drug. Each condition receives its own population code by amendment when its first eligible trial is included.",null,null,"inventory","Analyzed under the connectivity rule once it is met."]]}